Literature DB >> 2467316

Muscarinic receptor subtypes and the selectivity of agonists and antagonists.

N J Birdsall1, C A Curtis, P Eveleigh, E C Hulme, E K Pedder, D Poyner, M Wheatley.   

Abstract

Receptors may be grouped into superfamilies, according to their mechanism. Muscarinic receptors belong to one such superfamily, that of the G-protein coupled receptors. Subtypes of muscarinic receptors may be defined according to their primary amino acid sequence, their mechanism and their pharmacology. However, there is as yet no consistent scheme to explain the pharmacology and function of each molecular subtype. The pharmacological tools which distinguish between muscarinic receptor subtypes are described and the emerging evidence for the location of the ligand binding site is discussed.

Mesh:

Substances:

Year:  1988        PMID: 2467316     DOI: 10.1159/000138503

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  5 in total

1.  Regulation of synaptic plasticity in a schizophrenia model.

Authors:  Barbara Gisabella; Vadim Y Bolshakov; Francine M Benes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

2.  Evidence for facilitatory and inhibitory muscarinic receptors on postganglionic sympathetic nerves in mouse isolated atria.

Authors:  M Cost; H Majewski
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  Cholinergic stimulation of rat acinar cells increases c-fos and c-jun expression via a mitogen-activated protein kinase-dependent pathway.

Authors:  D J Turner; R A Cowles; B J Segura; M W Mulholland
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

4.  Differential effects of m1 and m2 receptor antagonists in perirhinal cortex on visual recognition memory in monkeys.

Authors:  Wei Wu; Richard C Saunders; Mortimer Mishkin; Janita Turchi
Journal:  Neurobiol Learn Mem       Date:  2012-04-26       Impact factor: 2.877

5.  The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.

Authors:  Jong Hoon Lee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-05       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.